Accessibility Log In Help Join The Motley Fool

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent Articles by Taylor Carmichael

GettyImages-1348326274

Sep 28, 2022 by Taylor Carmichael

The Shift to Crypto Gaming Is for Real

Here's how to play it.

GettyImages-1157565709

Sep 27, 2022 by Taylor Carmichael

3D Printing Is About to Explode; Here's 1 Way to Profit From It

After many years of disappointment, the promise of 3D printing is about to be fulfilled -- and Velo3D could be the top dog and first mover.

GettyImages-184292071

Sep 27, 2022 by Taylor Carmichael

Don't Worry About Stock-Picking Accuracy When You're Swinging for a Home Run

Babe Ruth was the king of home runs, and also the king of strikeouts. It's OK to invest like Babe Ruth.

GettyImages-468162128

Sep 25, 2022 by Taylor Carmichael

When Should You Sell Stocks?

2022 is a not a good year for selling high-growth stocks.

GettyImages-1023297106

Sep 25, 2022 by Taylor Carmichael, George Budwell, and Alex Carchidi

3 IPO Stocks That You Want to Own

This down market is giving us some really intriguing stocks at cheap prices.

GettyImages-625905650

Sep 24, 2022 by Taylor Carmichael

Silvergate Capital's Visionary Leadership Has Outsmarted the Big Banks

I am a big fan of Silvergate Capital and the bank's CEO, Alan Lane, as well as the rest of his management team.

GettyImages-506712124

Sep 12, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Stocks Expecting Good News From the FDA

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

GettyImages-949947128

Sep 4, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

These 3 Stocks Are the Future of Biotechnology

Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.

GettyImages-509541586

Sep 4, 2022 by Taylor Carmichael

Why I Sold a Healthcare Stock for a Cheap Internet Play

SmileDirectClub has a massive opportunity, but there are some pitfalls too; Farfetch has a monopoly position in its area of the fashion industry.

evolve-express-banner

Sep 4, 2022 by Taylor Carmichael

Here's the Next Stock I'm Going to Buy

This technological breakthrough in security could be an interesting buying opportunity.

GettyImages-465050849

Sep 2, 2022 by Taylor Carmichael

1 Growth Stock That's Played Out and 1 That's Just Starting

Hotels were a great buy during COVID-19. Now that growth story is over, and I've bought shares of a fast-grower in South America.

GettyImages-506712124

Aug 28, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Healthcare Stocks That Are Beating the Market

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.

GettyImages-1204177559

Aug 21, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Stocks to Buy and Hold for the Long Term

Here's why OrthoPediatrics, Compass Pathways, and Nano-X Imaging look like great stocks.

GettyImages-1205913548

Aug 21, 2022 by Taylor Carmichael

The Rise and Fall of Novavax

The story of Novavax stock over the last few years would make an amazing book.

GettyImages-1130966162

Aug 15, 2022 by Taylor Carmichael

What Stock Could Benefit Most From the Inflation Reduction Act?

The Act has $369 billion earmarked for U.S. energy security and fighting climate change. A lot of green companies will benefit, but one big winner will be MP Materials.

GettyImages-949947128

Aug 14, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Cathie Wood Stocks for the Future

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

GettyImages-1201549319

Aug 14, 2022 by Taylor Carmichael

2 Tips for Investing in Biotech Stocks With High Growth Potential

Investing in biotech stocks without any drugs on the market can be scary. These suggestions can help you make money in this high-risk sector.

RVac-sea-levelRaptor-1-1024x718

Aug 10, 2022 by Taylor Carmichael

Why Velo3D Stock Is Spiking 39% Today

The company just reported earnings, and the CEO has a prediction.

GettyImages-1277129101

Aug 10, 2022 by Taylor Carmichael

3 of the Cheapest Stocks I Own

Sea Limited, Farfetch, and Opendoor are all on sale right now.

GettyImages-1172262833

Aug 10, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Healthcare Stocks With High Profit Margins

If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.

HOW THE MOTLEY FOOL CAN HELP YOU

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

462%

S&P 500 Returns

125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services